JPH04244012A - Composition for oral cavity - Google Patents

Abstract

PURPOSE:To obtain a composition for oral cavity having action for suppressing formation of tartar. CONSTITUTION:A composition for oral cavity containing a casein decomposable polypeptide blended so as to improve tartar formation-preventing ability of a linear polyphosphoric acid salt known as a tartar formation-suppressing agent.

Description

[Detailed description of the invention]

0001

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to oral compositions, and more particularly to oral compositions in which the effectiveness of linear polyphosphate salts as tartar formation inhibitors is improved.

0002

2. Description of the Related Art Tartar is a dental deposit that is the main cause of gingivitis, periodontitis, etc., and inhibiting or removing its formation is necessary for the prevention and treatment of periodontal diseases. However, once tartar is deposited on the teeth, it becomes difficult to completely remove it. Such deposition is thought to occur because amorphous or microcrystalline calcium phosphate present in dental plaque gradually transforms into dense hydroxyapatite crystals. Therefore, by suppressing the formation of hydroxyapatite crystals, the formation of tartar can be effectively prevented.

[0003] Various proposals have been made to prevent and suppress such tartar formation, for example, in the Archives of Oral Biology (Arch. Oral.
iol. ), 15, 893-896 (1970) showed the effectiveness of soluble phosphate against dental calculus, and also reported that using a fluoride ion source and water-soluble pyrophosphate alone,
Alternatively, an anti-tartar composition for the oral cavity has been proposed, which is characterized by containing the composition in the form of a mixture (US Pat. No. 4,51
No. 5,772).

[0004] Also, Gaffer et al.
No. 9,712 showed that the combination of pyrophosphate and a hydrolyzed methoxyethylene:maleic anhydride (1:1) copolymer had a synergistic effect in inhibiting hydroxyapatite formation outside of biological conditions. ing.

[0005]

OBJECTS OF THE INVENTION The present inventors have conducted extensive research with the aim of further increasing the ability of linear polyphosphates to suppress the formation of dental calculus. As a result, the inventors discovered that the ability of linear polyphosphate to inhibit dental calculus formation was synergistically promoted by combining a linear polyphosphate with a casein-degrading polypeptide, thereby completing the present invention.

[0006]

SUMMARY OF THE INVENTION The present invention provides an oral composition comprising a linear polyphosphate and a caseinolytic polypeptide. Linear polyphosphates effective as inhibitors of tartar formation are usually used in the form of fully neutralized or partially neutralized water-soluble alkali metal or ammonium salts and mixtures thereof. Representative examples include sodium tripolyphosphate, tetrasodium pyrophosphate, tetrapotassium pyrophosphate, and disodium dihydrogen pyrophosphate. In the present invention, the linear polyphosphate is present in the composition from about 0.01 to
It is blended in an amount of 10% by weight, preferably 0.1 to 5% by weight. The caseinolytic polypeptide used is particularly preferably a peptide fraction containing phosphoserine obtained by hydrolyzing α-casein, β-casein, and K-casein, either alone or in a mixture. Such a substance is casein phosphopeptide (a mixture of α-casein phosphopeptide and β-casein phosphopeptide) obtained by hydrolyzing milk casein with a proteolytic enzyme (particularly trypsin). In the present invention, the caseinolytic polypeptide synergistically promotes the inhibitory effect of linear polyphosphate on dental calculus formation, and the amount thereof is at least 1/20 of the weight of the linear polyphosphate. Above, usually 1/20 ~
10 times is preferable. The oral composition of the present invention can be made into powdered toothpaste, toothpaste, mouthwash, lozenge, chewing gum, candy, etc. by mixing desired ingredients in a conventional manner, and can also be administered into the oral cavity as an aerosol. It can also be sprayed. It can also be used as a tooth coating agent, or by impregnating dental floss or toothpicks. Other components are not particularly limited, and those commonly used in this type of composition can be blended.

EXAMPLES The present invention will be explained in more detail by experiments and examples below, but the present invention is not limited to these examples. In the Examples, all "%" means "% by weight". Experiment 1 The inhibitory effect of the test solution on tartar formation was investigated by measuring the in vitro formation time of hydroxyapatite using a pH-stat method. 2.0 ml of each aqueous solution of the components shown in Table 1 below adjusted to various concentrations in an experimental system, and 2.0 ml of a 0.1 M sodium dihydrogen phosphate aqueous solution under a nitrogen atmosphere.
Added to 42 ml of CO2-free deionized distilled water in the reaction flask with continuous stirring. Then, 2.0 ml of 0.1M calcium chloride aqueous solution was added, and the pH was adjusted to 7.4 with sodium hydroxide. During this time, sodium dihydrogen phosphate and calcium chloride react to produce dibasic calcium phosphate, and during the transformation into hydroxyapatite, OH- ions are consumed and the pH decreases, so add 0.1N aqueous sodium hydroxide solution. Drop the pH to 7.
．． It was kept at 4. The amount of 0.1N sodium hydroxide aqueous solution consumed at this time was automatically recorded, and the time for hydroxyapatite formation was measured. The results are shown in Table 1. Note that this pH-stat method is widely used as a screening method for active ingredients that suppress tartar formation, and also has the ability to inhibit hydroxyapatite crystal growth in vitro and in vitro.
It has been found that there is a good correlation between the ability to suppress calcification in vo.

[Table 1] In the case of the control test, the hydroxyapatite production reaction proceeded in two stages. First, the base is rapidly consumed when the precipitate of amorphous calcium phosphate is formed (after 1 to 4 minutes), then the base consumption decreases, and then when the amorphous calcium phosphate is transformed into hydroxyapatite crystals (after 1 to 4 minutes).
A second rapid base consumption was observed at 20 min). Therefore, the delay or disappearance of the second rapid consumption of base means that the formation of hydroxyapatite crystals is suppressed. As is clear from Table 1, 20 ppm of tetrasodium pyrophosphate alone has a slight inhibitory effect on hydroxyapatite formation compared to the control, but 20 ppm of casein phosphopeptide has no inhibitory effect. However, 20 ppm of tetrasodium pyrophosphate and 20 ppm of casein phosphopeptide
When m was combined, the hydroxyapatite formation time was unexpectedly delayed, confirming that a synergistic effect was working. In addition, as a comparative experiment, when 20 ppm of tetrasodium pyrophosphate and 20 ppm of sodium caseinate were combined in the same manner, no synergistic effect was observed (21
minutes). Example 1 The following components were degassed, kneaded, and stirred in a conventional manner to produce a toothpaste. Ingredients
amount
Silicic anhydride
20.0% Tetrasodium pyrophosphate
2.0% casein phosphopeptide
1.0% sorbitol (70% aqueous solution)
60.0% Sodium carboxymethylcellulose 1.5% Sodium lauryl sulfate 1.5
% titanium oxide
1.0%
sodium fluoride
0.2% saccharin sodium 0
．． 3% fragrance
0.9
% purified water
Remaining Example 2 The following components were degassed, kneaded, and stirred in a conventional manner to produce a toothpaste. Ingredients
amount
Silicic anhydride
20.0% Sodium polyphosphate
1.0% casein phosphopeptide
0.2% sorbitol
40.0% glycerin

20.0% Sodium lauryl sulfate
1.0%
titanium oxide
1.0% Sodium fluoride
0.2% saccharin sodium
0.3%
fragrance
0.9%
purified water
Remaining Example 3 The following components were degassed, kneaded, and stirred in a conventional manner to produce a toothpaste. Ingredients
amount
Silicic anhydride
20.0% Tetrasodium pyrophosphate
1.0% casein phosphopeptide
0.1% sorbitol
60.0% Sodium lauryl sulfate 1.
0% Sodium N-acyl-L-glutamate 0.5% Titanium oxide
1
．． 0% sodium fluoride
0.2% saccharin sodium
0.3% de-d tocopherol acetate 0.05
% Fragrance
0.9%
purified water
Remaining Example 4 The following components were mixed and stirred in a conventional manner to produce a liquid gargle. Ingredients
amount
ethanol
10.0% glycerin
10.0% Polyoxyethylene polyoxy 1.5%
Propylene glycol Saccharin sodium
0.02% Sodium Benzoate
0.2% Tetrasodium pyrophosphate
0.5%
casein phosphopeptide
0.1% fragrance

0.3% purified water

Remaining Example 5 A lozenge was manufactured according to the conventional method using the following formulation. Ingredients
amount
maltose
50.0% glucose
40.0% gum arabic

5.0% fragrance

0.2% Tetrasodium pyrophosphate
1.0% casein phosphopeptide
0.2% l-menthol
0.1
% gelatin
2.0%
water
1.5% Example 6 Chewing gum was manufactured according to the conventional method using the following recipe. Ingredients
amount
gum base
23.0% calcium carbonate
3.0% Palatinose
40.
0% maltitol
33.0% fragrance
0.3% aspartame
0.1% Tetrasodium pyrophosphate 0.5%
casein phosphopeptide
0.1% Example 7 A candy was manufactured according to the conventional method using the following recipe. Ingredients
amount
sugar
40.0% starch syrup
58.7% fragrance

0.2% citric acid

0.5% Tetrasodium pyrophosphate
0.5%
casein phosphopeptide
0.1%

According to the present invention, an oral composition that promotes the inhibitory effect of linear polyphosphates on dental calculus formation and exhibits an excellent effect on preventing dental calculus formation can be obtained.

Claims (3)

[Claims] 1. An oral composition comprising a caseinolytic polypeptide and a linear polyphosphate. 2. The oral composition according to claim 1, wherein the caseinolytic polypeptide is a polypeptide containing phosphoserine. 3. The oral composition according to claim 1, wherein the casein-degrading polypeptide is a casein phosphopeptide.